Conference Call with SMS Pharmaceuticals Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company SMS Pharmaceuticals announced Q4FY26 & FY26 results Standalone Financial Highlights: Revenue from Operations: Q4FY26: Rs 23,794.75 lakh, compared to Rs 21,044.70 lakh in Q3FY26 (QoQ increase of 13.07%) and Rs 24,819.56 lakh in Q4FY25 (YoY decrease of 4.13%). FY26: Rs 88,687.10 lakh, compared to Rs 78,274.81 lakh in FY25 (YoY increase of 13.30%). Total Income: Q4FY26: Rs 24,052.19 lakh, compared to Rs 21,419.94 lakh in Q3FY26 (QoQ increase of 12.29%) and Rs 24,961.97 lakh in Q4FY25 (YoY decrease of 3.64%). FY26: Rs 89,522.48 lakh, compared to Rs 78,897.25 lakh in FY25 (YoY increase of 13.47%). Net Profit After Tax: Q4FY26: Rs 2,092.09 lakh, compared to Rs 2,333.80 lakh in Q3FY26 (QoQ decrease of 10.36%) and Rs 2,062.24 lakh in Q4FY25 (YoY increase of 1.45%). FY26: Rs 8,760.93 lakh, compared to Rs 6,838.12 lakh in FY25 (YoY increase of 28.12%). Earnings Per Share (Basic): FY26: Rs 9.58, compared to Rs 8.07 in FY25. Consolidated Financial Highlights: Revenue from Operations: Q4FY26: Rs 23,794.75 lakh, compared to Rs 21,044.70 lakh in Q3FY26 (QoQ increase of 13.07%) and Rs 24,819.56 lakh in Q4FY25 (YoY decrease of 4.13%). FY26: Rs 88,687.10 lakh, compared to Rs 78,274.81 lakh in FY25 (YoY increase of 13.30%). Net Profit After Tax: Q4FY26: Rs 2,096.45 lakh, compared to Rs 2,318.95 lakh in Q3FY26 (QoQ decrease of 9.60%) and Rs 2,008.29 lakh in Q4FY25 (YoY increase of 4.40%). FY26: Rs 8,799.79 lakh, compared to Rs 6,739.82 lakh in FY25 (YoY increase of 30.56%). Business Highlights: Dividend: The Board recommended a final dividend of Rs 0.40 per equity share (40%) on equity shares of face value of Rs 1/- each for FY26, subject to shareholder approval. Corporate Developments: Registered Office: The Board approved shifting the registered office of the Company from Banjara Hills, Hyderabad to Kondapur, Serilingampally, Hyderabad, effective May 25, 2026. Borrowing Limits: The Board approved an increase in borrowing limits from Rs 15,000 crore to Rs 20,000 crore, subject to shareholder approval. Auditor Appointments: M/s. Annapragada & Co., Cost Accountants, appointed as Cost Auditor for FY27. M/s. Adusumilli & Associates, Chartered Accountants, re-appointed as Internal Auditor for FY27. Segment Reporting: The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and their intermediates, which constitutes a single reportable business segment. Other Matters: During FY26, 50,00,000 warrants were converted into equity shares, increasing the paid-up equity share capital. The auditors issued an unmodified opinion on the financial results. Result PDF